Follow-up of conservatively managed prostate cancer Watchful waiting and primary hormonal therapy

Edward M. Messing, Ian Thompson

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Many men with newly diagnosed prostate cancer choose not to undergo curative treatment, including patients who cannot be helped by local curative therapies (especially those with metastatic disease) and patients with clinically localized disease who opt for expectant management or noncurative treatments such as androgen ablation. This article reviews the selection of patients for these noncurative approaches, strategies for clinical monitoring, the choices of intervention therapies upon progression, and when to start these therapies.

Original languageEnglish (US)
Pages (from-to)687-702
Number of pages16
JournalUrologic Clinics of North America
Volume30
Issue number4
DOIs
StatePublished - Nov 2003

Fingerprint

Watchful Waiting
Prostatic Neoplasms
Therapeutics
Patient Selection
Androgens

ASJC Scopus subject areas

  • Urology

Cite this

Follow-up of conservatively managed prostate cancer Watchful waiting and primary hormonal therapy. / Messing, Edward M.; Thompson, Ian.

In: Urologic Clinics of North America, Vol. 30, No. 4, 11.2003, p. 687-702.

Research output: Contribution to journalArticle

@article{410bfdef760f48868351ea6a131e2e58,
title = "Follow-up of conservatively managed prostate cancer Watchful waiting and primary hormonal therapy",
abstract = "Many men with newly diagnosed prostate cancer choose not to undergo curative treatment, including patients who cannot be helped by local curative therapies (especially those with metastatic disease) and patients with clinically localized disease who opt for expectant management or noncurative treatments such as androgen ablation. This article reviews the selection of patients for these noncurative approaches, strategies for clinical monitoring, the choices of intervention therapies upon progression, and when to start these therapies.",
author = "Messing, {Edward M.} and Ian Thompson",
year = "2003",
month = "11",
doi = "10.1016/S0094-0143(03)00050-8",
language = "English (US)",
volume = "30",
pages = "687--702",
journal = "Urologic Clinics of North America",
issn = "0094-0143",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Follow-up of conservatively managed prostate cancer Watchful waiting and primary hormonal therapy

AU - Messing, Edward M.

AU - Thompson, Ian

PY - 2003/11

Y1 - 2003/11

N2 - Many men with newly diagnosed prostate cancer choose not to undergo curative treatment, including patients who cannot be helped by local curative therapies (especially those with metastatic disease) and patients with clinically localized disease who opt for expectant management or noncurative treatments such as androgen ablation. This article reviews the selection of patients for these noncurative approaches, strategies for clinical monitoring, the choices of intervention therapies upon progression, and when to start these therapies.

AB - Many men with newly diagnosed prostate cancer choose not to undergo curative treatment, including patients who cannot be helped by local curative therapies (especially those with metastatic disease) and patients with clinically localized disease who opt for expectant management or noncurative treatments such as androgen ablation. This article reviews the selection of patients for these noncurative approaches, strategies for clinical monitoring, the choices of intervention therapies upon progression, and when to start these therapies.

UR - http://www.scopus.com/inward/record.url?scp=0344011550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344011550&partnerID=8YFLogxK

U2 - 10.1016/S0094-0143(03)00050-8

DO - 10.1016/S0094-0143(03)00050-8

M3 - Article

C2 - 14680308

AN - SCOPUS:0344011550

VL - 30

SP - 687

EP - 702

JO - Urologic Clinics of North America

JF - Urologic Clinics of North America

SN - 0094-0143

IS - 4

ER -